Tenaya Therapeutics, Inc. Other Noncash Income (Expense)
Tenaya Therapeutics, Inc. (TNYA) reported Other Noncash Income (Expense) of -$1.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-05
- Tenaya Therapeutics, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was -$1.14M.
- Tenaya Therapeutics, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was -$8.00K.
- Tenaya Therapeutics, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was -$130.00K.
- Tenaya Therapeutics, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was -$63.00K.
- Tenaya Therapeutics, Inc. other noncash income (expense) for fiscal 2025 was -$423.00K.
- Tenaya Therapeutics, Inc. other noncash income (expense) for fiscal 2024 was -$383.00K.
- Tenaya Therapeutics, Inc. other noncash income (expense) for fiscal 2023 was -$217.00K.
- Tenaya Therapeutics, Inc. other noncash income (expense) for fiscal 2022 was -$217.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.15M 10-Q · filed 2026-08-05 | -$1.28M derived: sum of 3 quarters · filed 2026-08-05 | -$1.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$8.00K 10-Q · filed 2026-05-06 | -$138.00K derived: sum of 2 quarters · filed 2026-05-06 | -$201.00K derived: sum of 3 quarters · filed 2026-05-06 | -$263.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$193.00K derived: sum of 2 quarters · filed 2026-03-11 | -$255.00K derived: sum of 3 quarters · filed 2026-08-05 | -$423.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | -$63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$125.00K derived: sum of 2 quarters · filed 2026-08-05 | -$293.00K 10-Q · filed 2025-11-10 | -$433.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$230.00K 10-Q · filed 2026-08-05 | -$370.00K derived: sum of 3 quarters · filed 2026-08-05 | -$459.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$168.00K 10-Q · filed 2026-05-06 | -$308.00K derived: sum of 2 quarters · filed 2026-05-06 | -$397.00K derived: sum of 3 quarters · filed 2026-05-06 | -$451.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$229.00K derived: sum of 2 quarters · filed 2026-03-11 | -$283.00K derived: sum of 3 quarters · filed 2026-03-11 | -$383.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | -$89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$143.00K derived: sum of 2 quarters · filed 2025-11-10 | -$243.00K 10-Q · filed 2025-11-10 | -$303.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$154.00K 10-Q · filed 2025-08-06 | -$214.00K derived: sum of 3 quarters · filed 2025-08-06 | -$266.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$100.00K 10-Q · filed 2025-05-07 | -$160.00K derived: sum of 2 quarters · filed 2025-05-07 | -$212.00K derived: sum of 3 quarters · filed 2025-05-07 | -$265.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$112.00K derived: sum of 2 quarters · filed 2025-03-10 | -$165.00K derived: sum of 3 quarters · filed 2025-03-10 | -$217.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | -$52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$105.00K derived: sum of 2 quarters · filed 2024-11-06 | -$157.00K 10-Q · filed 2024-11-06 | -$347.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$105.00K 10-Q · filed 2024-08-08 | -$295.00K derived: sum of 3 quarters · filed 2024-08-08 | -$294.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$52.00K 10-Q · filed 2024-05-14 | -$242.00K derived: sum of 2 quarters · filed 2024-05-14 | -$241.00K derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$190.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$189.00K derived: sum of 2 quarters · filed 2024-03-18 | -$217.00K 10-K · filed 2024-03-18 | |
| 2022-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$27.00K 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | -$28.00K 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | -$61.00K 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |